

Escitalopram oxalate: co-existence of oxalate dianions and oxalic acid molecules in the same crystal

William T. A. Harrison,^{a*} H. S. Yathirajan,^b S. Bindya,^b
 H. G. Anilkumar^b and Devaraju^b

^aDepartment of Chemistry, University of Aberdeen, Meston Walk, Aberdeen AB24 3UE, Scotland, and ^bDepartment of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570 006, India

Correspondence e-mail: w.harrison@abdn.ac.uk

Received 18 December 2006

Accepted 19 December 2006


Online 23 January 2007

The title compound {systematic name: (+)-(*S*)-3-[5-cyano-2-(4-fluorophenyl)-1,3-dihydroisobenzofuran-2yl]propanaminium oxalate oxalic acid 0.325-hydrate}, $2C_{20}H_{22}FN_2O^+ \cdot C_2O_4^{2-} \cdot C_2H_2O_4 \cdot 0.325H_2O$, is a molecular salt of the N-protonated escitalopram cation. As well as charge-balancing oxalate dianions, neutral molecules of oxalic acid are present. The component species interact by way of N—H···O and short

O—H···O hydrogen bonds, resulting in supramolecular chains.

Comment

(+)-(*S*)-1-[3-(Dimethylammonio)propyl]-1-(4-fluorophenyl)-5-phthalan-5-carbonitrile oxalate ($C_{20}H_{21}FN_2O$), common names escitalopram or *S*-(+)-citalopram, is a widely prescribed drug used to treat depression and related conditions (Burke, 2002). It is conveniently introduced as an oxalate salt, with a nominal formula usually given as $C_{20}H_{21}FN_2O \cdot C_2H_2O_4$, *i.e.* the presumed proton-transfer reaction is not specified (Sorbera *et al.*, 2001). As part of our ongoing crystallographic studies of pharmaceutical molecules (Harrison *et al.*, 2005), we now report the structure of the title compound, (I), in which two N-protonated escitalopram cations ($C_{20}H_{22}FN_2O^+$) and a $C_2O_4^{2-}$ oxalate dianion are accompanied by a neutral molecule of oxalic acid and a partially occupied water molecule (Fig. 1).



The bond lengths and angles in (I) fall within their expected ranges (Cambridge Structural Database, Version 5.27; Allen,




Figure 1

The molecular structure of (I), showing 50% probability displacement ellipsoids (arbitrary spheres for H atoms). All H atoms, except those involved in hydrogen bonds (dashed lines), have been omitted for clarity.

2002). There are two $C_{20}H_{22}FN_2O^+$ cations in the asymmetric unit; atoms C8 and C28 are assumed to possess *S* configurations, consistent with the known absolute structure of the biologically active enantiomer of citalopram (Sanchez *et al.*, 2004). For the C1-containing molecule, the dihedral angle between the mean planes of the C2–C7 and C9–C14 benzene rings is $62.83(13)^\circ$, and the C1/C2/C7/C8/O1 five-membered ring displays an envelope conformation with atom O1 in the flap position [the displacement from the C-atom mean plane is $0.435(5) \text{ \AA}$]. In the C21-containing molecule, the dihedral angle between the C22–C27 and C29–C34 mean planes is $81.99(13)^\circ$, and the envelope conformation for C21/C22/C27/C28/O2 is less pronounced, with atom O2 displaced from the C-atom mean plane by $0.113(6) \text{ \AA}$. The oxalate species are both approximately planar; the dihedral angle between the C41/O3/O4 and C42/O5/O6 groupings is $4.4(3)^\circ$, and the equivalent value for C43/O7/O8 and C44/O9/O10 is $2.8(6)^\circ$.

The component species in (I) interact by way of $N-H \cdots O$ and $O-H \cdots O$ hydrogen bonds (Table 1), such that both $C_{20}H_{22}FN_2O^+$ cations make bifurcated $N-H \cdots (O,O)$ hydrogen bonds to the same oxalate dianion. Then, the $2C_{20}H_{22}FN_2O^+ \cdot C_2O_4^{2-}$ units are linked into [001] chains by way of the oxalic acid molecules, *i.e.* the oxalate dianions and oxalic acid molecules alternate in the chains (Fig. 2). The short $H \cdots O$ separations of the oxalic acid-to-oxalate hydrogen bonds suggests that they are strong interactions.

Although it is not expected from a consideration of the pK_a values of oxalic acid ($pK_{a1} = 1.23$ and $pK_{a2} = 4.19$; Newkome *et al.*, 1985) the co-existence of oxalate dianions and oxalic acid molecules in the same crystal has been observed in a number of compounds, three examples being bis(pyridinium) oxalate oxalic acid (Newkome *et al.*, 1985), barium oxalate oxalic acid dihydrate (Chaix-Pluchery *et al.*, 1989) and 1-(α -pyrrolidiniobenzyl)-2-naphthol oxalate oxalic acid (Periasamy *et al.*, 2004). These three compounds show the same alternating oxalate–oxalic acid hydrogen-bonded chains seen in (I).




Figure 2

A view along [010] of part of an [001] chain in (I), with hydrogen bonds shown as dashed lines. Atoms labelled with an asterisk (*) are generated by the symmetry operation $(x, y, z - 1)$.

Experimental

The title compound was obtained as a gift sample from Jubilant Organosys, Nanjangud, India. The sample of (I) was recrystallized from ethanol (m.p. 420 K).

Crystal data

$2C_{20}H_{22}FN_2O^+ \cdot C_2O_4^{2-} \cdot C_2H_2O_4 \cdot 0.325H_2O$	$V = 2094.54(14) \text{ \AA}^3$
$M_r = 834.05$	$Z = 2$
Monoclinic, $P2_1$	$D_x = 1.324 \text{ Mg m}^{-3}$
$a = 7.9355(3) \text{ \AA}$	Mo $K\alpha$ radiation
$b = 24.7376(9) \text{ \AA}$	$\mu = 0.10 \text{ mm}^{-1}$
$c = 11.1332(5) \text{ \AA}$	$T = 120(2) \text{ K}$
$\beta = 106.589(2)^\circ$	Block, colourless
	$0.32 \times 0.24 \times 0.18 \text{ mm}$

Data collection

Nonius KappaCCD diffractometer	7581 measured reflections
ω and φ scans	3609 independent reflections
Absorption correction: multi-scan (SADABS; Bruker, 2003)	2652 reflections with $I > 2\sigma(I)$
$T_{\min} = 0.969$, $T_{\max} = 0.982$	$R_{\text{int}} = 0.037$
	$\theta_{\max} = 25.5^\circ$

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0473P)^2]$
$R[F^2 > 2\sigma(F^2)] = 0.042$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.095$	$(\Delta/\sigma)_{\max} = 0.008$
$S = 1.02$	$\Delta\rho_{\max} = 0.17 \text{ e \AA}^{-3}$
3609 reflections	$\Delta\rho_{\min} = -0.21 \text{ e \AA}^{-3}$
562 parameters	Extinction correction: SHELXL97
H atoms treated by a mixture of independent and constrained refinement	Extinction coefficient: 0.0118 (16)

Table 1

Hydrogen-bond geometry (\AA , $^\circ$).

$D-H \cdots A$	$D-H$	$H \cdots A$	$D \cdots A$	$D-H \cdots A$
$N1-H1 \cdots O6$	0.93	1.91	2.768 (4)	152
$N1-H1 \cdots O4$	0.93	2.22	2.886 (4)	128
$N3-H2 \cdots O3$	0.93	1.91	2.764 (4)	152
$N3-H2 \cdots O5$	0.93	2.22	2.884 (4)	127
$O7-H3 \cdots O5$	0.91 (3)	1.56 (3)	2.466 (4)	177 (4)
$O9-H4 \cdots O4^i$	0.91 (3)	1.57 (3)	2.465 (4)	173 (4)

Symmetry code: (i) $x, y, z + 1$.

Anomalous dispersion effects were negligible and Friedel pairs were merged before refinement. The absolute structure of (I) was assigned on the basis of the known chirality of escitalopram (Sanchez *et al.*, 2004). The C- and N-bound H atoms were placed in idealized locations ($C-H = 0.95\text{--}0.99 \text{ \AA}$ and $N-H = 0.93 \text{ \AA}$) and refined as riding with $U_{\text{iso}}(\text{H})$ values of $1.2U_{\text{eq}}(\text{carrier})$ or $1.5U_{\text{eq}}(\text{methyl C})$. The oxalic acid H atoms were located in a difference map and refined with the restraint $O-H = 0.90(1) \text{ \AA}$ and the constraint $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{O})$. The H atoms of the partially occupied water molecule could not be located.

Data collection: COLLECT (Nonius, 1998); cell refinement: SCALEPACK (Otwinowski & Minor, 1997); data reduction: SCALEPACK and DENZO (Otwinowski & Minor, 1997), and SORTAV (Blessing, 1995); program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: ORTEP-3 (Farrugia, 1997); software used to prepare material for publication: SHELXL97.

We thank the EPSRC National Crystallography Service (University of Southampton) for data collection.

Supplementary data for this paper are available from the IUCr electronic archives (Reference: GD3075). Services for accessing these data are described at the back of the journal.

References

- Allen, F. H. (2002). *Acta Cryst.* **B58**, 380–388.
- Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.
- Bruker (2003). *SADABS*. Bruker AXS Inc., Madison, Wisconsin, USA.
- Burke, W. J. (2002). *Expert Opin. Invest. Drugs*, **11**, 1477–1486.
- Chaix-Pluchery, O., Mutin, J. C., Bouillot, J. & Niepce, J. C. (1989). *Acta Cryst.* **C45**, 1699–1705.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Harrison, W. T. A., Yathirajan, H. S., Anilkumar, H. G., Sarojini, B. K., Narayana, B. & Lobo, K. G. (2005). *Acta Cryst.* **E61**, o3810–o3812.
- Newkome, G. R., Theriot, K. J. & Fronczek, F. R. (1985). *Acta Cryst.* **C41**, 1642–1644.
- Nonius (1998). *COLLECT*. Nonius BV, Delft, The Netherlands.
- Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr & R. M. Sweet, pp. 307–326. New York: Academic Press.
- Periasamy, M., Reddy, M. N. & Anwar, S. (2004). *Tetrahedron Asymmetry*, **15**, 1809–1812.
- Sanchez, C., Bogeso, K. P., Ebert, B., Reines, E. H. & Braestrup, C. (2004). *Psychopharmacology*, **174**, 163–176.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Sorbera, L. A., Revel, L., Martin, L. & Castaner, J. (2001). *Drugs Future*, **26**, 115–120.